Multi-Year Contract Extension with Nycomed for Genedata Screener
News Jan 15, 2008
Genedata has announced a multi-year contract extension for the use of the Genedata Screener® discovery product suite with Nycomed. Taking a trusted collaboration to the next level, Genedata will create a global scientific computing infrastructure for the lead discovery and drug research programs at Nycomed sites worldwide.
Independent of instrumentation, technology, volume or location, Genedata Screener will enable the interdisciplinary teams at all sites to capture, visualize, analyze and manage large volumes of assay data. Low to ultra-high throughput screens, single-point assays or complex high content screens will all benefit from Screener`s high performance and flexibility.
The combination of these findings with data from other corporate sources, accessible through Screener`s powerful viewing tools, will provide Nycomed scientists with the range of information they need to enhance their lead finding processes – anywhere on the globe.
Dr. Werner Stürmer, Head of HTS at Nycomed, explained, “Genedata Screener not only improves the efficiency and quality of our screening campaigns, but also has a catalytic impact on our global information network – increasing the number of users and promoting accurate and timely decisions across departments and countries."
Dr. Stephan Heyse, Head of the Genedata Screener Business Unit, added, “Our high performance and advanced quality control capabilities together with the established professional services and low maintenance cost will help to ease time constraints and to streamline communication, while generating high-quality results.”
In of organic chemistry, reactions are notoriously difficult to analyze. As a result, reaction data in chemoinformatics has been much less developed than information about single molecules. In a new project, titled CGRtools, researchers solved a number of problems to better handle reaction information. The software library is significantly richer in functionality than all the existing tools.READ MORE
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE